IMS Health Holdings Inc

IMS Health — Merger or Acquisition (May 2016)

30 slides from IMS Health's merger presentation, May 3, 2016

  1. Slide 1: Investor Briefing May 3, 2016

    Slide 1: Investor Briefing May 3, 2016

    Investor Briefing May 3, 2016 Exhibit 99.2

  2. Slide 2: Cautionary Statements Regarding Forward Looking Statements

    Slide 2: Cautionary Statements Regarding Forward Looking Statements

    Cautionary Statements Regarding Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

  3. Slide 3: Important Information About the Transaction and Where to Find It

    Slide 3: Important Information About the Transaction and Where to Find It

    Important Information About the Transaction and Where to Find It In connection with the proposed transaction, IMS Health and Quintiles will be filing documents with the Securities and Exchange Commission (“SEC”), including the filing by Quintiles of a registration statement on Form S-4, and Quintile

  4. Slide 4: Introducing global healthcare intelligence

    Slide 4: Introducing global healthcare intelligence

    Introducing Global healthcare intelligence to measure and realize value from R&D and Commercial execution to real world patient outcomes Information-powered, technology-enabled, differentiated solutions to address life science’s most pressing issues

  5. Slide 5: At-A-Glance: 2015 Combined Financial View

    Slide 5: At-A-Glance: 2015 Combined Financial View

    At-A-Glance 2015 Combined Financial View $7.2B 2015 Revenue2 $17.6B Market Capitalization1 $1.7B 2015 Adj. EBITDA3 $1.3B 2015 Adj. UFCF4 Transformational Merger of Equals $23.0B Enterprise Value1 As of May 2, 2016 equity market close; net debt as of March 31, 2016 Based on 2015 Quintiles service rev

  6. Slide 6: Significant Shareholder Value Creation

    Slide 6: Significant Shareholder Value Creation

    Significant Shareholder Value Creation Faster Growth Differentiated and diversified solutions to address massive unmet needs 100-200 bps of anticipated incremental annual revenue growth rate captured by end of year 3 Cost Savings EPS Accretion Balance Sheet Flexibility $100M of estimated annual run-

  7. Slide 7: Merger Summary

    Slide 7: Merger Summary

    Merger Summary Structure and Exchange Ratio All-stock merger of equals Expected to be tax free to IMS Health and Quintiles shareholders 0.384 shares of IMS Health stock to be exchanged for each share of Quintiles stock Committed financing has been obtained to refinance certain debt Ownership Pro for

  8. Slide 8: Transformational Partner to Life Sciences

    Slide 8: Transformational Partner to Life Sciences

    Transformational Partner to Life Sciences World Class Talent Serving World Class Clients Multiple Value Creation Levers Compelling Financial Profile

  9. Slide 9: Two Best-in-Class Businesses

    Slide 9: Two Best-in-Class Businesses

    Two Best-in-Class Businesses 2015 Metrics Differentiated Resources Leading Capabilities Revenue: $4.3B Adj. EBITDA / Margin(1): $819M / 19% >1,100 medical doctors, ~1,050 PhDs, ~850 biostatisticians & statistical programmers Quintiles Infosario® platform: >298,000 clinical investigators, clinical re

  10. Slide 10: Life Sciences Challenges

    Slide 10: Life Sciences Challenges

    Life Sciences Challenges Realize Greater R&D Efficiency Demonstrate Value & Measure Outcomes Maximize Commercial ROI $140B+ biopharmaceutical R&D spend per year 1 34% increase since 2010 in cost to develop new drug 2 11.3% clinical success rate (IND Filing to Approval) 2 Increasing study complexity

  11. Slide 11: Game Changing Solutions

    Slide 11: Game Changing Solutions

    Transformational Partner To Life Sciences Game Changing Solutions Realize Greater R&D Efficiency Demonstrate Value & Measure Outcomes Maximize Commercial ROI Smarter CRO Real World Evidence & Connected Health Technology-Enabled Commercial Operations Equipping therapeutic, scientific, and domain expe

  12. Slide 12: Estimated >$230B Market Opportunity

    Slide 12: Estimated >$230B Market Opportunity

    Transformational Partner To Life Sciences Estimated >$230B Market Opportunity Growing At 6-8% Growth Drivers Smarter CRO: Need: modernize global trial execution Opportunity: bring information and technology from design through execution of studies Real World Evidence & Connected Health: Need: enable

  13. Slide 13: The Smarter CRO

    Slide 13: The Smarter CRO

    Transformational Partner To Life Sciences The Smarter CRO 530M+ anonymous patient records 14M+ healthcare professional reference database; 70+ countries 500k clinical investigators Information assets in 90 markets 430+ direct-to patient studies Data collection experience from ~5,700 studies Global E

  14. Slide 14: Real World Evidence & Connected Health

    Slide 14: Real World Evidence & Connected Health

    Transformational Partner To Life Sciences Real World Evidence & Connected Health Strategic Levers Create Lifecycle Evidence Partner Technology-enabled retrospective and prospective approaches to support scientific and commercial needs Demonstrate Treatment Value Globally Global infrastructure to eva

  15. Slide 15: Technology-Enabled Commercial Operations

    Slide 15: Technology-Enabled Commercial Operations

    Transformational Partner To Life Sciences Technology-Enabled Commercial Operations Strategic Levers Shape R&D and Commercial Convergence Align R&D clinical knowledge with commercial analytics and sales execution Orchestrate Customer Engagement Leverage global information and technology tools to mana

  16. Slide 16: World Class Talent

    Slide 16: World Class Talent

    World Class Talent ~50,000 Strong Employee Base 15,000+ employees serving clients across 100+ countries 1,200+ healthcare informatics experts worldwide 7,000+ employees in commercial services 3,000+ offshore delivery employees Quintiles 36,000+ employees serving clients across 100+ countries 1,100+

  17. Slide 17: World Class Clients

    Slide 17: World Class Clients

    World Class Clients Top 25 customers measured by 2015 revenue. Retention rates measured from 2014-2015. Largest customer measured by contribution to 2015 revenue. IMS Health: 5,000+ clients Top 25 customers with IMS >25 years on average; 99% retention for top 1,000 customers RWE engagements in each

  18. Slide 18: Compelling Financial Profile: Global Scale and Diversification

    Slide 18: Compelling Financial Profile: Global Scale and Diversification

    Compelling Financial Profile Global Scale and Diversification Combined 2015 Revenue of $2.9B 2015 Revenue of $4.3B 2015 Revenue of $7.2B(1) Asia Pacific Americas EMEA Americas Asia Pacific EMEA EMEA Americas Asia Pacific Definition of geographical revenue mix may differ by company. This presentation

  19. Slide 19: Strong Balance Sheet and Free Cash Flow

    Slide 19: Strong Balance Sheet and Free Cash Flow

    $4.3B $3.9B $2.5B $1.5B $6.8B $5.4B Gross Debt Leverage Net Debt Leverage Compelling Financial Profile Strong Balance Sheet and Free Cash Flow 2015 Combined Unlevered Free Cash Flow(2) of Est. $1.3B Combined Leverage ratios are calculated using Adjusted EBITDA. See appendix for reconciliations. See

  20. Slide 20: Accelerating Top-line Growth

    Slide 20: Accelerating Top-line Growth

    Smarter CRO Real World Evidence Technology Enabled Commercial Operations 100-200 bps of Estimated Incremental Annual Revenue Growth Rate by End of Year 3 Note: Actual synergies and other cost savings may differ materially from the current expectations, and neither IMS nor Quintiles can assure invest

  21. Slide 21: Savings to Increase Earnings Growth

    Slide 21: Savings to Increase Earnings Growth

    Annual Estimated Run-rate Cost Savings $100M by End of Year 3 SG&A IT Infrastructure & Support Operations Development Note: Actual synergies and other cost and tax savings may differ materially from the current expectations, and neither IMS nor Quintiles can assure investors that they will achieve t

  22. Slide 22: Accelerating the Momentum of Two World-Class Franchises

    Slide 22: Accelerating the Momentum of Two World-Class Franchises

    Accelerating The Momentum of Two World-Class Franchises Note: Actual synergies and other cost and tax savings may differ materially from the current expectations, and neither IMS nor Quintiles can assure investors that they will achieve the full amount of the estimated synergies on schedule or at al

  23. Slide 23: Appendix: Non-GAAP Financial Measures

    Slide 23: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures

  24. Slide 24: Quintiles Net Income to Adjusted EBITDA

    Slide 24: Quintiles Net Income to Adjusted EBITDA

    Quintiles Net Income to Adjusted EBITDA Change in estimated fair value of contingent consideration on business combinations.

  25. Slide 25: IMS Health Net Income to Adjusted EBITDA

    Slide 25: IMS Health Net Income to Adjusted EBITDA

    Stock-based compensation related charges are included in Operating costs of information, Direct and incremental costs of technology services and Selling and administrative expenses as follows: Restructuring and related charges includes severance and impairment charges and the cost of employee and th

  26. Slide 26: Quintiles Unlevered Free Cash Flow

    Slide 26: Quintiles Unlevered Free Cash Flow

    Quintiles Unlevered Free Cash Flow

  27. Slide 27: IMS Health Unlevered Free Cash Flow

    Slide 27: IMS Health Unlevered Free Cash Flow

    IMS Health Unlevered Free Cash Flow Acquisition-related charges are included primarily in Selling and administrative expenses.

  28. Slide 28: Quintiles Gross and Net Leverage Ratio

    Slide 28: Quintiles Gross and Net Leverage Ratio

    Quintiles Gross and Net Leverage Ratio

  29. Slide 29: IMS Health Gross and Net Leverage Ratio

    Slide 29: IMS Health Gross and Net Leverage Ratio

    IMS Health Gross and Net Leverage Ratio

  30. Slide 30: Q&A

    Slide 30: Q&A

    Q&A

Source: SEC EDGAR · 425 filed May 3, 2016

More decks from IMS Health Holdings Inc